XML 44 R33.htm IDEA: XBRL DOCUMENT v3.8.0.1
Acquisitions, Divestitures, Research Collaborations and License Agreements - Acquisitions Narrative (Details)
€ in Millions
1 Months Ended 9 Months Ended
Oct. 31, 2017
USD ($)
Oct. 31, 2017
EUR (€)
Jul. 31, 2017
USD ($)
Mar. 31, 2017
USD ($)
Jul. 31, 2016
USD ($)
Jun. 30, 2016
USD ($)
Jan. 31, 2016
USD ($)
Sep. 30, 2017
USD ($)
Sep. 30, 2016
USD ($)
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]                      
Goodwill               $ 18,340,000,000   $ 18,162,000,000  
Contingent consideration               945,000,000 $ 894,000,000 $ 891,000,000 $ 590,000,000
Contingent milestone payment               $ 100,000,000 $ 25,000,000    
Rigontec | Subsequent event                      
Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]                      
Cash paid for acquisition of business $ 140,000,000 € 119                  
Amount of potential future additional payments for milestones, maximum | €   € 349                  
Vallee SA                      
Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]                      
Cash paid for acquisition of business       $ 358,000,000              
Percentage of business acquired (as percent)       93.50%              
Escrow deposit       $ 176,000,000              
Intangible assets       291,000,000              
Deferred tax liabilities noncurrent       93,000,000              
Other net assets       15,000,000              
Noncontrolling interest       25,000,000              
Contingent liabilities       37,000,000              
Indemnification assets       37,000,000              
Goodwill       $ 170,000,000              
Discount rate (as percent)       15.50%              
Acquired finite-lived intangible assets, weighted average useful life       15 years              
Afferent Pharmaceuticals                      
Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]                      
Cash paid for acquisition of business         $ 487,000,000            
Amount of potential future additional payments for milestones, maximum         750,000,000            
Deferred tax liabilities noncurrent         258,000,000            
Other net assets         29,000,000            
Goodwill         $ 130,000,000            
Discount rate (as percent)         11.50%            
Consideration transferred         $ 510,000,000            
In-process research and development (IPR&D)         832,000,000            
Contingent consideration         223,000,000            
StayWell Company                      
Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]                      
Cash paid for acquisition of business         150,000,000            
Intangible assets         238,000,000            
Deferred tax liabilities noncurrent         84,000,000            
Noncontrolling interest         124,000,000            
Goodwill         $ 275,000,000            
Acquired finite-lived intangible assets, weighted average useful life         10 years            
Debt         $ 150,000,000            
Period before option becomes exercisable         3 years            
Other net liabilities         $ 5,000,000            
Useful life         5 years            
Moderna Therapeutics                      
Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]                      
Upfront and milestone payments made to collaborative partner           $ 200,000,000          
IOmet Pharma Ltd                      
Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]                      
Cash paid for acquisition of business             $ 150,000,000        
Amount of potential future additional payments for milestones, maximum             250,000,000        
Goodwill             $ 57,000,000        
Discount rate (as percent)             10.50%        
In-process research and development (IPR&D)             $ 155,000,000        
Contingent consideration             94,000,000        
Deferred tax assets noncurrent             $ 32,000,000        
Contingent milestone payment     $ 100,000,000